AMENDMENTS TO THE CLAIMS

1. A method for inducing an immune response, comprising:

topically administering to a subject an oil-in-water emulsion and an immunostimulatory nucleic acid in an effective amount to induce an immune response.

2.-40 (Canceled)

41.-61. (Canceled)

62. (New) The method of claim 1, wherein the immune response is an antigen specific immune response.

63. (New) The method of claim 1, further comprising administering an antigen.

64. (New) The method of claim 1, wherein the immunostimulatory nucleic acid is a CpG immunostimulatory nucleic acid.

65. (New) The method of claim 1, wherein the subject has a cancer.

66. (New) The method of claim 1, wherein the subject has an infectious disease.

67. (New) The method of claim 1, wherein the subject is at risk of developing an infectious disease.

68. (New) The method of claim 66 or 67, wherein the infectious disease is a bacterial infection or a fungal infection.

69. (New) The method of claim 66 or 67, wherein the infectious disease is a viral infection.

(New)

70. The method of claim 69, wherein the viral infection is a human papilloma virus infection, a herpes simplex virus infection or a herpes zoster virus infection.

71. The method of claim 1, wherein the oil-in-water emulsion and the immunostimulatory nucleic acid is administered to the skin.

72. The method of claim 1, wherein the oil-in-water emulsion and the immunostimulatory nucleic acid is administered to a mucosal surface.

73. The method of claim 72, wherein the mucosal surface is an oral surface, a rectal surface, a nasal surface, a vaginal surface or an ocular surface.

74. The method of claim 1, further comprising administering an anti-viral agent.

75. The method of claim 74, wherein the anti-viral agent is selected from the group consisting of Acemannan; Acyclovir; Acyclovir Sodium; Adefovir; Alovudine; Alvircept Sudotox; Amantadine Hydrochloride; Aranotin; Arildone; Atevirdine Mesylate; Avridine; Cidofovir; Cipamfylline; Cytarabine Hydrochloride; Delavirdine Mesylate; Desciclovir; Didanosine; Disoxaril; Edoxudine; Enviradene; Enviroxime; Famciclovir; Famotine Hydrochloride; Fiacitabine; Fialuridine; Fosarilate; Foscarnet Sodium; Fosfonet Sodium; Ganciclovir; Ganciclovir Sodium; Idoxuridine; Kethoxal; Lamivudine; Lobucavir; Memotine Hydrochloride; Methisazone; Nevirapine; Penciclovir; Pirodavir; Ribavirin; Rimantadine Hydrochloride; Saquinavir Mesylate; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine; Tilorone Hydrochloride; Trifluridine; Valacyclovir Hydrochloride; Vidarabine; Vidarabine Phosphate; Vidarabine Sodium Phosphate; Viroxime; Zalcitabine; Zidovudine; and Zinviroxime.

76. The method of claim 65, wherein the cancer is selected from the group consisting of melanoma , basal cell carcinoma, and cervical cancer.

77. The method of claim 1, wherein the immunostimulatory nucleic acid has a modified backbone.

78. The method of claim 77, wherein the modified backbone is a phosphate modified backbone.

79. The method of claim 78, wherein the phosphate modified backbone is a phosphorothioate modified backbone.

80. The method of claim 78, wherein the modified backbone is a peptide modified oligonucleotide backbone.

81. The method of claim 1, wherein the subject is an immunocompromised subject.

82. The method of claim 1, wherein the immunostimulatory nucleic acid has the nucleotide sequence of TCG TCG TTT CGT CGT TTT GTC GTT (SEQ ID NO:150).

83. The method of claim 1, wherein the immunostimulatory nucleic acid and oil-in-water emulsion is formulated for mucosal delivery.

84. The method of claim 1, wherein the immunostimulatory nucleic acid and oil-in-water emulsion is formulated for oral deliver, ocular delivery, nasal delivery, vaginal delivery or rectal delivery.

85. The method of claim 1, wherein the immunostimulatory nucleic acid and oil-in-water emulsion is formulated for skin delivery.

86. The method of claim 1, wherein the immunostimulatory nucleic acid has the nucleotide sequence of TCG TCG TTT TGT CGT TTT GTC GTT (SEQ ID NO:147), TCG TCG TTT CGT CGT TTC GTC GTT (SEQ ID NO:148), TCG TCG TTT TTC GGT CGT TTT (SEQ ID NO:149), TCG TCG TTT TGT CGT TTT TTT CGA (SEQ ID NO:151), or TCG TCG TTT TTC GTG CGT TTT T (SEQ ID NO:152).

87. The method of claim 1, wherein the immunostimulatory nucleic acid has the nucleotide seqeunce of TCGTCGTTGTCGTTTTGTCGTT (SEQ ID NO:153).

88. The method of claim 1, wherein the subject has or is at risk of developing a condition selected from the group consisting of contact dermatitis, eczema, psoriasis, atopic dermatitis, allergic contact dermatitis, and latex dermatitis.

89. The method of claim 1, wherein the immunostimulatory nucleic acid is a class A immunostimulatory nucleic acid, a class C immunostimulatory nucleic acid, a semi-soft immunostimulatory nucleic acid or a soft immunostimulatory nucleic acid.

90. The method of claim 1, wherein the subject has or is at risk of developing basal cell carcinoma and the immunostimulatory nucleic acid is TCG TCG TTT TGT CGT TTT GTC GTT (SEQ ID NO:147).

91. The method of claim 1, wherein the immune response is an innate immune response.

92. The method of claim 1, wherein the immune response is an adaptive immune response.

93. The method of claim 1, wherein the immune response is a local immune response.

94. The method of claim 1, wherein the subject is actively exposed to an antigen.

95. The method of claim 1, wherein the subject is passively exposed to an antigen.